Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 16, 2012

View Archived Issues

Marketed anticancer drug shows potential to treat Alzheimer's disease

Trimel provides update on intranasal gel for female anorgasmia

NIH to fund development of next-generation biodefense vaccines

Small-molecule interferon receptor agonist holds promise to treat hepatitis C

Analyte-responsive microscale pumps designed at Penn State

Large-scale European phase III study to assess nilvadipine

Summit discloses phase I study plans for candidate DMD treatment

FDA approves second-generation prostate cancer test

Novel P13K inhibitors patented by Roche

Recruitment begins in phase II ISIS-APOCIIIRx trial

EpiTherapeutics divulges new GASC-1 inhibitors

Phase II ofatumumab/GSK-2110183 combination study enters recruitment phase

Novel metabotropic glutamate mGlu4 receptor modulators identified

Shire reports active fourth quarter 2011

RedHill Biopharma begins advanced-stage clinical trial of RHB-102

Bionor provides update on development of HIV vaccine

Glenveigh Medical digoxin antidote gets orphan drug designation

FDA accepts NDA for tafamidis

Edgemont Pharmaceuticals obtains license to market CPI-300 in U.S.

New serotonin receptor antagonists patented in Japan

Ono Pharmaceutical updates progress of third quarter of fiscal 2011

Bristol-Myers Squibb develops new candidate cancer therapeutics

Multicenter study validates prognostic tool for use in patients comatose after cardiac arrest

Renal function marker is associated with severity of cerebral small vessel disease

Pfizer presents novel candidate pain treatments

FDA approves new gel for male hypogonadism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...